An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Hemodialysis Patients

Trial Profile

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Hemodialysis Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Relypsa
  • Most Recent Events

    • 28 Apr 2016 Results published in a Relypsa Inc. media release.
    • 28 Apr 2016 According to Relypsa media release, data were presented at National Kidney Foundation 2016 Spring Clinical Meetings.
    • 21 Apr 2016 According to Relypsa media release, data will be presented at National Kidney Foundation 2016 Spring Clinical Meetings.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top